The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3

M. A. Fischl, L. Resnick, R. Coombs, A. B. Kremer, J. C. Pottage, R. J. Fass, Kenneth Fife, W. G. Powderly, A. C. Collier, R. L. Aspinall, S. L. Smith, K. G. Kowalski, C. B. Wallemark

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC- 48334) (an α-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated ≤ 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo. Sixty patients received combination therapy and 58, zidovudine and placebo. Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15). The mean SC-48334 steady-state trough level (4.04 ± 0.99 μg/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients. Although superiority of combination therapy was not seen, these data suggest that SC-48334 has anti-HIV activity and provide a rationale for the evaluation of better tolerated compounds of this class.

Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume7
Issue number2
StatePublished - 1994
Externally publishedYes

Fingerprint

Zidovudine
Virus Diseases
HIV-1
Safety
HIV
miglustat
Therapeutics
Placebos
Flatulence
Abdominal Pain
Weight Loss
Diarrhea

Keywords

  • Combination therapy
  • Glucosidase inhibitor
  • HIV
  • N-Butyl-deoxynojirimycin (SC-48334)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Virology

Cite this

Fischl, M. A., Resnick, L., Coombs, R., Kremer, A. B., Pottage, J. C., Fass, R. J., ... Wallemark, C. B. (1994). The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. Journal of Acquired Immune Deficiency Syndromes, 7(2), 139-147.

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. / Fischl, M. A.; Resnick, L.; Coombs, R.; Kremer, A. B.; Pottage, J. C.; Fass, R. J.; Fife, Kenneth; Powderly, W. G.; Collier, A. C.; Aspinall, R. L.; Smith, S. L.; Kowalski, K. G.; Wallemark, C. B.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 7, No. 2, 1994, p. 139-147.

Research output: Contribution to journalArticle

Fischl, MA, Resnick, L, Coombs, R, Kremer, AB, Pottage, JC, Fass, RJ, Fife, K, Powderly, WG, Collier, AC, Aspinall, RL, Smith, SL, Kowalski, KG & Wallemark, CB 1994, 'The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3', Journal of Acquired Immune Deficiency Syndromes, vol. 7, no. 2, pp. 139-147.
Fischl, M. A. ; Resnick, L. ; Coombs, R. ; Kremer, A. B. ; Pottage, J. C. ; Fass, R. J. ; Fife, Kenneth ; Powderly, W. G. ; Collier, A. C. ; Aspinall, R. L. ; Smith, S. L. ; Kowalski, K. G. ; Wallemark, C. B. / The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. In: Journal of Acquired Immune Deficiency Syndromes. 1994 ; Vol. 7, No. 2. pp. 139-147.
@article{87f845bb75ad49dfb42f3f9174fcdde2,
title = "The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3",
abstract = "We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC- 48334) (an α-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated ≤ 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo. Sixty patients received combination therapy and 58, zidovudine and placebo. Twenty-three patients (38{\%}) and 15 (26{\%}), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15). The mean SC-48334 steady-state trough level (4.04 ± 0.99 μg/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40{\%}) and two (11{\%}) at week 4 (p = 0.10) and five (45{\%}) and two (14{\%}) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients. Although superiority of combination therapy was not seen, these data suggest that SC-48334 has anti-HIV activity and provide a rationale for the evaluation of better tolerated compounds of this class.",
keywords = "Combination therapy, Glucosidase inhibitor, HIV, N-Butyl-deoxynojirimycin (SC-48334)",
author = "Fischl, {M. A.} and L. Resnick and R. Coombs and Kremer, {A. B.} and Pottage, {J. C.} and Fass, {R. J.} and Kenneth Fife and Powderly, {W. G.} and Collier, {A. C.} and Aspinall, {R. L.} and Smith, {S. L.} and Kowalski, {K. G.} and Wallemark, {C. B.}",
year = "1994",
language = "English (US)",
volume = "7",
pages = "139--147",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3

AU - Fischl, M. A.

AU - Resnick, L.

AU - Coombs, R.

AU - Kremer, A. B.

AU - Pottage, J. C.

AU - Fass, R. J.

AU - Fife, Kenneth

AU - Powderly, W. G.

AU - Collier, A. C.

AU - Aspinall, R. L.

AU - Smith, S. L.

AU - Kowalski, K. G.

AU - Wallemark, C. B.

PY - 1994

Y1 - 1994

N2 - We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC- 48334) (an α-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated ≤ 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo. Sixty patients received combination therapy and 58, zidovudine and placebo. Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15). The mean SC-48334 steady-state trough level (4.04 ± 0.99 μg/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients. Although superiority of combination therapy was not seen, these data suggest that SC-48334 has anti-HIV activity and provide a rationale for the evaluation of better tolerated compounds of this class.

AB - We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC- 48334) (an α-glucosidase I inhibitor) and zidovudine versus zidovudine alone. Patients with 200 to 500 CD4 cells/mm3 who tolerated ≤ 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo. Sixty patients received combination therapy and 58, zidovudine and placebo. Twenty-three patients (38%) and 15 (26%), in the combination and zidovudine groups, respectively, discontinued therapy (p = 0.15). The mean SC-48334 steady-state trough level (4.04 ± 0.99 μg/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients. Although superiority of combination therapy was not seen, these data suggest that SC-48334 has anti-HIV activity and provide a rationale for the evaluation of better tolerated compounds of this class.

KW - Combination therapy

KW - Glucosidase inhibitor

KW - HIV

KW - N-Butyl-deoxynojirimycin (SC-48334)

UR - http://www.scopus.com/inward/record.url?scp=0028088988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028088988&partnerID=8YFLogxK

M3 - Article

C2 - 7905523

AN - SCOPUS:0028088988

VL - 7

SP - 139

EP - 147

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -